LA LABDosing, Reconstitution & Safety (2026)
Cagrilintide is a research peptide studied as a once-weekly shot for appetite and weight outcomes. It is a long-acting amylin analogue — a synthetic version of amylin, the hormone the pancreas releases alongside insulin after a meal to signal that you are full. Researchers study it because it works on a satiety pathway that is separate from GLP-1, which is why it is most often paired with GLP-1 compounds like semaglutide (the combination known as "CagriSema").
This guide covers the typical research-protocol structure: a low 0.25 mg start, slow weekly titration up to 2.4 mg, how to reconstitute the 10 mg vial, how to plan supplies, and what the Phase 2 monotherapy and Phase 3 CagriSema data show. It is an educational reference. It is not medical advice and not a personal treatment plan.
Cagrilintide dosing is built as a slow climb, not a dose to jump into. Phase 2 monotherapy studied fixed once-weekly doses from 0.3 mg up to 4.5 mg, with the strongest weight effect at the higher end. The 2.4 mg dose is the level carried into the Phase 3 CagriSema program, paired 1:1 with semaglutide 2.4 mg.
Because amylin analogues cause the same dose-dependent nausea seen with GLP-1 compounds, the research titration mirrors the semaglutide-style escalation: start low, hold each dose for about 4 weeks, and only step up once the current dose is tolerated.
Common Research Titration (Weekly)
| Phase | Weeks | Weekly Dose | Notes |
|---|---|---|---|
| Initiation | Weeks 1–4 | 0.25 mg | Starting dose. Goal is tolerance, not results. Minimal appetite effect expected. |
| Early escalation | Weeks 5–8 | 0.5 mg | First step up. Mild nausea or early fullness may begin. |
| Mid escalation | Weeks 9–12 | 1 mg | Appetite suppression usually becomes noticeable. |
| High escalation | Weeks 13–16 | 1.7 mg | Intermediate step before target dose. |
| Therapeutic target | Weeks 17+ | 2.4 mg | The dose carried into Phase 3 CagriSema. Hold and reassess. |
Cycle Guidelines
| Approach | Duration | Review Point | Best For |
|---|---|---|---|
| Phase 2 monotherapy reference | 26 weeks | Every 4 weeks at each dose step | Matches the original Lancet 2021 trial structure. |
| CagriSema-style (with GLP-1) | 68 weeks | Every 4 weeks during titration | Mirrors the Phase 3 combination target of 2.4 mg + semaglutide 2.4 mg. |
| Slow titration | Add 2–4 weeks per step when GI symptoms persist | Each dose step | When nausea, vomiting, or constipation is hard to tolerate. |
Plan based on the once-weekly schedule above, using LA LAB's 10 mg vial reconstituted with 2.0 mL bacteriostatic water (5 mg/mL). The standard climb is 0.25 → 0.5 → 1 → 1.7 → 2.4 mg weekly.
Peptide Vials — 10 mg Vial (2 mL BAC)
LA LAB stocks Cagrilintide as a 10 mg vial. With 2.0 mL BAC water, concentration is 5 mg/mL — so 1 mg = 20 units on a U-100 syringe. One 10 mg vial provides about 4 doses at the 2.4 mg target, or many more at lower titration doses.
| Cycle Length | Planning Note |
|---|---|
| 4 weeks | 0.25 mg × 4 = 1 mg total — one 10 mg vial covers it many times over. |
| 8 weeks | 0.25 + 0.5 mg phases = 3 mg total — one 10 mg vial. |
| 16 weeks | Through the 1.7 mg phase ≈ 13.8 mg total — 2 × 10 mg vials. |
| 26 weeks | Through the 2.4 mg phase ≈ 32 mg total — 4 × 10 mg vials give margin. |
Insulin Syringes — U-100, 0.5 mL
One syringe per weekly injection. A 0.5 mL (50-unit) syringe comfortably measures the full range, including the 48-unit draw at the 2.4 mg target dose.
| Cycle Length | Planning Note |
|---|---|
| 8 weeks | 8 syringes per weekly injection. |
| 16 weeks | 16 syringes per weekly injection. |
| 26 weeks | 26 syringes per weekly injection; a 100-count box gives margin. |
Bacteriostatic Water — 2 mL per Vial
Reconstitute each 10 mg vial with 2.0 mL BAC water. 10 mL bottles are the common research-supply size and cover several vials.
| Cycle Length | Planning Note |
|---|---|
| 16 weeks | 2 × 10 mg vials → 4.0 mL. One 10 mL bottle covers it. 1 × 10 mL bottle. |
| 26 weeks | 4 × 10 mg vials → 8.0 mL. One 10 mL bottle covers it. 1 × 10 mL bottle. |
Reconstitution answers two questions. First, how much bacteriostatic water to add to the lyophilised vial. Second, how many syringe units match each weekly dose after mixing. Read across the row for your target dose.
Reconstitution Math — 10 mg Vial (2 mL BAC → 5 mg/mL)
| Target Dose | Units (U-100) | Doses / Vial |
|---|---|---|
| 0.25 mg | 5.0 units | 40 |
| 0.5 mg | 10.0 units | 20 |
| 1 mg | 20.0 units | 10 |
| 1.7 mg | 34.0 units | 5.9 |
| 2.4 mg | 48.0 units | 4.2 |
Step-by-Step Reconstitution
Cagrilintide is a long-acting analogue of amylin, a hormone your pancreas co-secretes with insulin after eating. Amylin is one of the body's natural "meal is over" signals. Cagrilintide is engineered to stay active far longer than natural amylin, so that signal is maintained across the week rather than fading within hours.
Amylin & Calcitonin Receptors (the 'Fullness' Levers)
Cagrilintide activates amylin receptors — and, because of structural overlap, calcitonin receptors — in the hindbrain (the area postrema) and hypothalamus, the brain regions that regulate appetite. This promotes satiety, so meals feel satisfying sooner and hunger returns more slowly.
Slowed Gastric Emptying
Like GLP-1 compounds, amylin signalling slows the rate at which food leaves the stomach. Food stays in the stomach longer, which reinforces fullness and reduces the drive to eat between meals.
A Pathway Separate from GLP-1
The important distinction is that amylin works through its own receptor system, not the GLP-1 receptor. That is why cagrilintide and semaglutide are complementary: they suppress appetite through two independent axes, and combining them (CagriSema) produced greater results in trials than either compound on its own.
Structurally, cagrilintide is a modified amylin peptide with a fatty-acid (lipidation) attachment that binds to albumin in the blood. That binding is the technical reason for its long half-life (roughly 7 days) and once-weekly dosing.
Cagrilintide is studied in adults with obesity or overweight, most extensively in combination with semaglutide (CagriSema). It is not approved for any use as of August 2026, so eligibility is defined by the trials, not by a label.
Trial Exclusion Patterns
Cagrilintide and CagriSema trials commonly excluded participants with a history of pancreatitis, medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2), severe gastroparesis, recent major cardiovascular events, severe kidney impairment, type 1 diabetes, and pregnancy or breastfeeding — the same general pattern used in semaglutide and tirzepatide trials.
Pregnancy, Breastfeeding, and Trying to Conceive
Cagrilintide has not been studied in pregnant or breastfeeding people. Trials require effective contraception. Anyone in those situations should not be considering cagrilintide outside qualified medical care.
Conditions That Need Clinician Oversight
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis or gallbladder disease
- Severe kidney or liver disease
- Severe GI conditions (gastroparesis, IBD flare)
- Active cardiovascular disease or recent cardiac event
- Use of insulin or sulfonylureas (hypoglycaemia risk, especially in combination protocols)
Cagrilintide's side-effect profile looks broadly similar to other appetite-acting research compounds: mostly gastrointestinal symptoms that appear during dose escalation and ease as the body adjusts. In trials it was generally well tolerated, and the combination with semaglutide did not add a distinct new safety signal beyond the expected GI effects.
Common Gastrointestinal Effects
| Effect | Pattern |
|---|---|
| Nausea | Most common; dose-dependent, usually mild–moderate, worst during escalation. |
| Constipation | Common; linked to slowed gastric emptying. |
| Vomiting | Less common; typically during step-ups. |
| Decreased appetite / early fullness | Expected pharmacology rather than an adverse effect. |
Other Observations
- Injection site reactions (redness, itching, small nodules) were observed in a minority of participants.
- Amylin analogues can slow gastric emptying enough to affect the absorption of other oral medications taken at the same time — a point for clinician oversight.
- In combination (CagriSema) protocols, hypoglycaemia risk rises for anyone also using insulin or sulfonylureas.
Cagrilintide builds up slowly. Steady-state plasma concentrations land after about 4–5 half-lives, or roughly 4 weeks at each dose step. That is why each titration phase is about 4 weeks long — it gives the dose time to reach a steady level before the next step up.
Half-Life and Steady State
Cagrilintide's half-life is roughly 7 days, which supports once-weekly dosing. After stopping, it takes roughly 5 half-lives (about 5 weeks) for the compound to clear.
Weight Loss in Trials
| Study | Regimen | Result |
|---|---|---|
| Phase 2 monotherapy (Lancet 2021) | Cagrilintide 4.5 mg weekly, 26 weeks | Up to ~10.8% body weight loss (vs ~3% placebo) |
| Phase 1b combination | Cagrilintide 2.4 mg + semaglutide 2.4 mg | ~17% at 20 weeks (early combination data) |
| Phase 3 CagriSema (REDEFINE-1) | Cagrilintide 2.4 mg + semaglutide 2.4 mg, 68 weeks | ~22.7% average body weight loss |
Reasonable Markers to Track
- Weekly body weight on the same scale at the same time of day.
- Notes on GI symptoms by dose phase — the single most useful data point for deciding when to hold a dose.
- Routine labs (CBC, CMP, lipid panel, fasting glucose, HbA1c) before starting and on a regular schedule under clinician oversight.
- Blood glucose if using cagrilintide alongside insulin or a sulfonylurea.
Human Evidence — Phase 2 Monotherapy (Lau et al., Lancet 2021)
A dose-finding trial of once-weekly cagrilintide (0.3–4.5 mg) versus placebo and liraglutide 3.0 mg in adults with obesity, over 26 weeks. The 4.5 mg dose produced up to ~10.8% body weight loss, exceeding placebo (~3%) and comparable to or better than liraglutide (~9%). Established the once-weekly amylin-analogue concept.
Human Evidence — Phase 1b/2 Combination (CagriSema)
Combining cagrilintide 2.4 mg with semaglutide 2.4 mg produced greater weight loss than either agent alone in earlier combination studies, supporting the dual-pathway (amylin + GLP-1) rationale and the move to Phase 3.
Human Evidence — Phase 3 CagriSema (REDEFINE-1, Novo Nordisk 2024)
In adults with obesity or overweight without diabetes, cagrilintide 2.4 mg + semaglutide 2.4 mg produced an average body weight reduction of about 22.7% at 68 weeks — one of the higher figures reported for an injectable weight-management regimen. Detailed results reported through Novo Nordisk's REDEFINE program.
Lyophilised powder is more temperature-tolerant than reconstituted solution. Short shipping exposure for sealed powder is usually less of a concern than poor storage after the vial is mixed.
| State | Storage | Notes |
|---|---|---|
| Lyophilised (powder), sealed | -4°F (-20°C) or below (frozen) | Long-term; up to 12+ months. |
| Lyophilised (powder), sealed | 35.6–46.4°F (2–8°C) | Several months. |
| Lyophilised (powder), short shipping | Room temperature short-term | Stable for several weeks; powder tolerates short-term temperature swings. |
| Reconstituted (liquid form) | 35.6–46.4°F (2–8°C) | Use within 2–4 weeks; protect from light. |
| Reconstituted (liquid form) | -4°F (-20°C) (frozen aliquots) | Up to 3–4 months; avoid repeat freeze-thaw. |
Missed Dose
If a scheduled weekly dose is missed and a few days have passed, the dose can generally be taken when remembered; if it is close to the next scheduled dose, skip it and resume on the normal day. Do not double up. This mirrors general clinical-trial guidance and is not a personal medical recommendation.
Cloudy or Off-Colour Vial
Reconstituted cagrilintide should be clear. A cloudy, particulate, or strongly off-colour solution is a sign to stop using that vial and check storage, BAC water, and reconstitution technique.
Wrong BAC Water Volume
Adding too much or too little BAC water changes the concentration and the syringe units per dose. If the volume was off, recalculate using the actual amount added. Example: at 2.0 mL the vial is 5 mg/mL and 2.4 mg = 48 units; at 1.0 mL it would be 10 mg/mL and 2.4 mg = 24 units.
Nausea Feels Too Strong
Holding the current dose for an extra 2–4 weeks before stepping up is the main lever for GI tolerance. Smaller, more frequent meals and staying hydrated are common research-community strategies. Do not push to 2.4 mg faster than the body tolerates.
Injection Site Reaction
Small redness, itching, or a tender bump at the injection site is common. Rotate sites by at least an inch each week. Persistent or growing reactions need a clinician.
The simplest way to place cagrilintide is by the hormone system it acts on. Semaglutide and retatrutide act on the GLP-1 (incretin) family. Cagrilintide acts on the amylin system — a separate satiety pathway. That is exactly why it is combined with GLP-1 rather than competing with it.
| Category | Cagrilintide | Semaglutide | Tirzepatide |
|---|---|---|---|
| Hormone class | Amylin analogue | GLP-1 agonist | GLP-1 + GIP agonist |
| Receptor targets | Amylin + calcitonin | GLP-1 | GLP-1 + GIP |
| Half-life | ~7 days | ~7 days | ~5 days |
| Dose frequency | Once weekly | Once weekly | Once weekly |
| Best studied as | Combination partner (CagriSema) | Standalone | Standalone |